Claims for Patent: 9,757,452

Summary for Patent: 9,757,452

Title:	Methods of treatment of keloid using an anti-VEGF agent
Abstract:	Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject.
Inventor(s):	Pham; Randal Tanh Hoang (San Jose, CA)
Assignee:
Application Number:	14/861,943
Patent Claims:	1. A method for treating keloid recurrence, the method comprising administering (1) an anti-VEGF-A agent to a site where a keloid has been removed from a subject. 2. The method of claim 1, wherein the anti-VEGF-A agent is an anti-VEGF-A antibody. 3. The method of claim 1, wherein the anti-VEGF-A agent is the antibody bevacizumab. 4. The method according to claim 3, wherein the bevacizumab is administered at a dose of 10 mg. 5. The method of claim 3, wherein the bevacizumab is administered at a dose in the range of about 5-15 mg. 6. The method of claim 1, wherein the anti-VEGF-A agent is administered by injection or topically. 7. The method of claim 6, wherein the anti-VEGF-A agent is injected at or adjacent to a site of new blood vessel growth at the site of keloid removal. 8. The method of claim 1, further comprising administering to the site (2) an anti-inflammatory steroid or (3) a non-steroidal anti-inflammatory drug (NSAID), or both. 9. The method of claim 8, wherein an anti-inflammatory steroid is administered to the site, and the anti-inflammatory steroid is applied topically, systemically, or by injection to the site of keloid removal. 10. The method of claim 9, an NSAID is administered to the site, and wherein the NSAID is diclofenac. 11. The method of claim 8, wherein an anti-inflammatory steroid is administered to the site, and the anti-inflammatory steroid is alclometasone, diflorasone, fluocinonide, or prednicarbate. 12. The method of claim 8, wherein the anti-VEGF-A agent is bevacizumab, the anti-inflammatory steroid is alclometasone, diflorasone, fluocinonide, or prednicarbate, and the NSAID is diclofenac. 13. The method of claim 1, further comprising administering to the site one or more subsequent administrations of one or more of an anti-VEGF-A agent, an anti-inflammatory steroid, and an NSAID. 14. The method of claim 1, wherein the anti-VEGF-A agent is a small molecule inhibitor of VEGF signaling. 15. The method of claim 1, wherein the anti-VEGF-A agent is selected from the group consisting of bevacizumab, ranibizumab, pegaptanib, imatinib, vandetanib, sorafenib, pazopanib, valatanib, vevasiranib, aflibercept, etanercept, squalamine lactate, erlotinib, and gefitinib.

Details for Patent 9,757,452

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2032-12-28
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2032-12-28
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2032-12-28
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2032-12-28
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2032-12-28
Immunex Corporation	ENBREL	etanercept	Injection	103795			2032-12-28